Madzia Crossley appointed as Junior Group Leader
Dr Magdalena (Madzia) Crossley will be joining the Cancer Research UK Cambridge Institute as a Junior Group Leader starting in early 2025.
Crossley completed her PhD at the University of Cambridge before accepting a Postdoctoral Scholar position at Stanford University, US. Since 2021, she has held a Stanford Cancer Institute Fellowship.
Crossley’s research will focus on understanding RNA – DNA hybrid structures called R loops, how they contribute to cells becoming cancerous, and whether they can be used to detect cancer in the clinic.
RNA is a molecule that carries instructions from DNA to make proteins. While DNA is the long-term storage of genetic information, RNA is the short-term messenger. Sometimes, after being made from DNA, RNA can reattach to the DNA, forming a structure called an R-loop.
R-loops can help influence how genes are turned on or off and are involved in normal cellular processes. However, if R-loops exist for too long or form in the wrong locations, they can cause issues, like increasing the risk of DNA breaks and instability.
Previous research by Dr Magdalena Crossley discovered that differences in how R-loops are processed can cause RNA-DNA hybrid molecules to build up inside the cell and trigger an immune system response.
Her new research group at the Institute will investigate how these RNA-DNA hybrids, which occur at higher levels in cancer cells, are made, how cells respond to the presence of these molecules and how these processes might contribute to cancer developing. They will analyse the molecules to try and identify patterns that can be linked to specific cancer types to classify and better understand tumours.
Finally, they aim to discover how these RNA-DNA hybrid molecules are released from cells and whether they can be found in the blood of cancer patients to be used as biomarkers to detect cancer. This could potentially lead to new, non-invasive methods for diagnosing and tracking cancer.
Related News
See all news-
Dr Guiping Wang appointed as a Junior Group Leader
18th May 2026
Dr Guiping Wang joins the Cancer Research UK Cambridge Institute as a Junior Group Leader, starting in September 2026.
Find out more -
Shankar Balasubramanian receives the Princess of Asturias Award for Scientific and Technical Research
14th May 2026
The 2026 award recognises Prof Balasubramanian and his co-recipients David Klenerman and Pascal Meyer for their pioneering work in genome sequencing technologies.
Find out more -
Prof Sir Steve Jackson receives the 2026 Galen Medal in Therapeutics
14th May 2026
This award comes in recognition of his transformational work on the mechanisms of DNA repair, cell survival and the DNA-damage response (DDR), as well as for the development of the cancer-targeting drug Olaparib.
Find out more